Background information
Epstein-Barr virus (EBV) is a human γ-herpesvirus with B cell growth–transforming ability and carcinogenic potential. More than 90% of human adults are infected with EBV. In healthy individuals, EBV typically establishes a persistent latent infection, in which the virus can be detected in resting, non-proliferating peripheral B lymphocytes.
The Epstein-Barr nuclear antigen 1 (EBNA-1) protein is involved in the replication of viral episomes and therefore crucial for the persistence of the infection. Its expression is maintained in all latency cycles of infection and in all EBV-associated malignancies.
Applications
T cells are essential for the control of the outgrowth of EBV-infected B cells. EBNA-1–specific CD4
+ and CD8
+ T cells have been found in EBV-infected individuals.
1–7Adoptive transfer of EBNA-1–specific T cells may be an effective tool for the treatment of EBV-associated malignancies.
In vitro stimulation of EBNA-1–specific CD4
+ and CD8
+ T cells with MACS GMP PepTivator EBV EBNA-1 causes the production of the effector cytokine IFN-γ. The secretion of IFN-γ then permits the enrichment of EBNA-1–specific effector/memory T cells using the CliniMACS
® Cytokine Capture System (IFN-gamma).
Quality statement
MACS GMP Products are manufactured and tested under a quality management system (ISO 13485) and are in compliance with relevant GMP guidelines. They are designed following the recommendations of USP <1043> on ancillary materials.
